Briumvi
ublituximab · Neuraxpharm Pharmaceuticals S.L.
AUTHORISED IN THE EUWhat Briumvi is used for
Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Briumvi
- Active substance
- ublituximab
- Disease area
- Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
- Medicine group
- Immunosuppressants
- ATC code
- L04
- Marketing authorisation holder
- Neuraxpharm Pharmaceuticals S.L.
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Briumvi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Briumvi used for?
Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
What is the active substance in Briumvi?
Briumvi contains ublituximab.
Who makes Briumvi?
The EU marketing authorisation holder is Neuraxpharm Pharmaceuticals S.L..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU